Compare Genuine Parts Company (GPC) vs Novavax Inc (NVAX) Price & Performance

GPC trades at $133.47, down 0.8% today, with a bullish technical trend and strong institutional support. Recent Q2 2026 earnings beat estimates with EPS of $2.15 versus $2.08 expected, driven by 6% sales growth. The stock is near its 52-week high, supported by a consensus price target of $148.67, though net income margins remain thin at 0.13%.

Outlook is positive with analyst consensus leaning buy, but risks include compressed profitability and high P/E ratio. The dividend yield adds income appeal, yet margin pressures from inflation and competition warrant caution for growth-focused investors.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.